• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多种白细胞介素 (IL)-17 家族细胞因子通过白细胞介素-17 受体 A 发出信号,驱动银屑病相关炎症途径。

Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.

机构信息

LEO Pharma A/S, Ballerup, Denmark.

Rockefeller University, New York, NY, USA.

出版信息

Br J Dermatol. 2021 Sep;185(3):585-594. doi: 10.1111/bjd.20090. Epub 2021 May 31.

DOI:10.1111/bjd.20090
PMID:33792895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8453543/
Abstract

BACKGROUND

The interleukin (IL)-23/IL-17 immune axis is of central importance in psoriasis. However, the impact of IL-17 family cytokines other than IL-17A in psoriasis has not been fully established.

OBJECTIVES

To elucidate the contribution of IL-17 family cytokines in psoriasis.

METHODS

To address the expression and localization of IL-17 family cytokines, lesional and nonlesional skin samples from patients with psoriasis were analysed by several complementary methods, including quantitative polymerase chain reaction, immunoassays, in situ hybridization and immunohistochemistry. Mechanistic studies assessing the functional activity of IL-17 family cytokines were performed using ex vivo cultured human skin biopsies and primary human keratinocytes.

RESULTS

We demonstrated that IL-17A, IL-17F, IL-17A/F and IL-17C are expressed at increased levels in psoriasis lesional skin and induce overlapping gene expression responses in ex vivo cultured human skin that correlate with the transcriptomic signature of psoriasis skin. Furthermore, we showed that brodalumab, in contrast to ixekizumab, normalizes gene expression responses induced by the combination of IL-17A, IL-17F, IL-17A/F and IL-17C in human keratinocytes.

CONCLUSIONS

Several IL-17 ligands signalling through IL-17RA are overexpressed in psoriasis skin and induce similar psoriasis-related inflammatory pathways demonstrating their relevance in relation to therapeutic intervention in psoriasis.

摘要

背景

白细胞介素(IL)-23/IL-17 免疫轴在银屑病中具有重要作用。然而,IL-17A 以外的 IL-17 家族细胞因子在银屑病中的作用尚未完全确定。

目的

阐明 IL-17 家族细胞因子在银屑病中的作用。

方法

为了研究 IL-17 家族细胞因子的表达和定位,采用多种互补方法分析了银屑病患者皮损和非皮损皮肤样本,包括定量聚合酶链反应、免疫测定、原位杂交和免疫组织化学。使用体外培养的人皮肤活检和原代人角质形成细胞进行了评估 IL-17 家族细胞因子功能活性的机制研究。

结果

我们证明了在银屑病皮损皮肤中,IL-17A、IL-17F、IL-17A/F 和 IL-17C 的表达水平升高,并在体外培养的人皮肤中诱导重叠的基因表达反应,与银屑病皮肤的转录组特征相关。此外,我们还表明,与依奇珠单抗相比,布罗达单抗可使 IL-17A、IL-17F、IL-17A/F 和 IL-17C 联合诱导的人角质形成细胞基因表达反应正常化。

结论

几种通过 IL-17RA 信号传导的 IL-17 配体在银屑病皮肤中过度表达,并诱导类似的银屑病相关炎症途径,证明它们与银屑病的治疗干预相关。

相似文献

1
Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.多种白细胞介素 (IL)-17 家族细胞因子通过白细胞介素-17 受体 A 发出信号,驱动银屑病相关炎症途径。
Br J Dermatol. 2021 Sep;185(3):585-594. doi: 10.1111/bjd.20090. Epub 2021 May 31.
2
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.银屑病皮损中白细胞介素-17亚型及受体的特征分析
Br J Dermatol. 2009 Feb;160(2):319-24. doi: 10.1111/j.1365-2133.2008.08902.x. Epub 2008 Oct 21.
3
Brodalumab: A new way to inhibit IL-17 in psoriasis.布罗达单抗:治疗银屑病中抑制白细胞介素-17的新方法。
Dermatol Ther. 2020 May;33(3):e13403. doi: 10.1111/dth.13403. Epub 2020 Apr 27.
4
IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.在克罗恩病患者抗TNF诱导的银屑病样皮肤病变中,白细胞介素-36γ与白细胞介素-17C维持促炎自我放大循环。
Inflamm Bowel Dis. 2014 Nov;20(11):1891-901. doi: 10.1097/MIB.0000000000000198.
5
Involvement of IL-17F via the induction of IL-6 in psoriasis.在银屑病中,IL-17F 通过诱导 IL-6 而发挥作用。
Arch Dermatol Res. 2010 Sep;302(7):499-505. doi: 10.1007/s00403-010-1033-8. Epub 2010 Feb 11.
6
Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.白细胞介素-17 受体 D 构成白细胞介素-17A 的替代受体,在银屑病样皮肤炎症中起重要作用。
Sci Immunol. 2019 Jun 7;4(36). doi: 10.1126/sciimmunol.aau9657.
7
Expression of IL-33 in the epidermis: The mechanism of induction by IL-17.IL-33 在表皮中的表达:IL-17 诱导的机制。
J Dermatol Sci. 2013 Aug;71(2):107-14. doi: 10.1016/j.jdermsci.2013.04.014. Epub 2013 Apr 19.
8
Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.抗 TNF-α 治疗可优先抑制银屑病皮肤中 p38 丝裂原活化蛋白激酶调节细胞因子的 mRNA 表达。
Br J Dermatol. 2010 Dec;163(6):1194-204. doi: 10.1111/j.1365-2133.2010.10036.x.
9
IL-17C and its receptor IL-17RA/IL-17RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer.白细胞介素-17C及其受体白细胞介素-17RA/白细胞介素-17RE将人类口腔上皮细胞识别为复发性阿弗他溃疡中的炎性细胞。
J Oral Pathol Med. 2014 Feb;43(2):117-24. doi: 10.1111/jop.12095. Epub 2013 Jul 3.
10
Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.白细胞介素 (IL)-17/IL-36 轴参与炎症性皮肤反应过程中内皮细胞和角质形成细胞之间的串扰。
PLoS One. 2020 Apr 30;15(4):e0222969. doi: 10.1371/journal.pone.0222969. eCollection 2020.

引用本文的文献

1
Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.布罗达单抗作为银屑病的二线治疗药物:生物制剂治疗失败后的快速反应及独特作用机制
Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9.
2
Macrophagic Ym1 orchestrates γδT cell-derived IL-17 production and keratinocyte functionality to mediate psoriasis-like skin inflammation.巨噬细胞Ym1协调γδT细胞衍生的IL-17产生和角质形成细胞功能,以介导银屑病样皮肤炎症。
Commun Biol. 2025 Aug 8;8(1):1186. doi: 10.1038/s42003-025-08628-1.
3
Galectin-9: diverse roles in skin disease.

本文引用的文献

1
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病(BE VIVID):一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
2
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性(BE READY):一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
3
半乳糖凝集素-9:在皮肤病中的多种作用。
Front Allergy. 2025 Jul 16;6:1614277. doi: 10.3389/falgy.2025.1614277. eCollection 2025.
4
An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis.一项无偏倚的组织转录组分析确定了特应性皮炎皮肤表型和治疗反应的潜在标志物。
Nat Commun. 2025 Jun 2;16(1):4981. doi: 10.1038/s41467-025-59340-x.
5
Interventions in cytokine signaling: novel horizons for psoriasis treatment.细胞因子信号传导干预:银屑病治疗的新视野
Front Immunol. 2025 Apr 15;16:1573905. doi: 10.3389/fimmu.2025.1573905. eCollection 2025.
6
Brodalumab: Six-Year US Pharmacovigilance Report.布罗达单抗:美国六年药物警戒报告。
Dermatol Ther (Heidelb). 2025 Jan;15(1):213-222. doi: 10.1007/s13555-024-01304-y. Epub 2024 Nov 26.
7
Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.免疫介导性皮肤病的治疗途径:战略治疗决策指南
Immune Netw. 2024 Aug 14;24(5):e33. doi: 10.4110/in.2024.24.e33. eCollection 2024 Oct.
8
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.IL-23 的过去、现在和未来:推进 IL-23 科学和治疗的路线图。
Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.
9
Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis.革兰氏阴性厌氧菌会引起强烈的角质形成细胞免疫反应,这可能为 HS 的发病机制提供新的见解。
Exp Dermatol. 2024 May;33(5):e15087. doi: 10.1111/exd.15087.
10
The Immunology of Psoriasis-Current Concepts in Pathogenesis.《银屑病的免疫学——发病机制的当前概念》。
Clin Rev Allergy Immunol. 2024 Apr;66(2):164-191. doi: 10.1007/s12016-024-08991-7. Epub 2024 Apr 20.
Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.布罗达单抗在先前使用白细胞介素-17A抑制剂治疗失败的中重度银屑病患者中取得成功。
J Am Acad Dermatol. 2021 Apr;84(4):1169-1171. doi: 10.1016/j.jaad.2020.11.013. Epub 2020 Nov 19.
4
Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.结构分析揭示细胞因子 IL-17F 与受体 IL-17RC 形成同源二聚体复合物,以驱动 IL-17RA 非依赖性信号转导。
Immunity. 2020 Mar 17;52(3):499-512.e5. doi: 10.1016/j.immuni.2020.02.004.
5
Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study.同一类别内的变化:白介素 17A 阻滞剂治疗斑块状银屑病后使用布罗达umab 的疗效 - 一项回顾性多中心研究。
J Dermatolog Treat. 2021 Dec;32(8):878-882. doi: 10.1080/09546634.2020.1716932. Epub 2020 Mar 6.
6
IL-17E (IL-25) and IL-17A Differentially Affect the Functions of Human Keratinocytes.白细胞介素-17E(白细胞介素-25)和白细胞介素-17A 对人角质形成细胞功能的影响存在差异。
J Invest Dermatol. 2020 Jul;140(7):1379-1389.e2. doi: 10.1016/j.jid.2019.12.013. Epub 2020 Jan 18.
7
Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.白介素-17 受体 A 拮抗剂治疗银屑病的短期转录反应。
J Allergy Clin Immunol. 2020 Mar;145(3):922-932. doi: 10.1016/j.jaci.2019.10.041. Epub 2019 Dec 27.
8
IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema.IL-17C 增强人类银屑病和特应性皮炎中的上皮炎症。
J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. doi: 10.1111/jdv.16126. Epub 2020 Jan 19.
9
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.在先前的抗白细胞介素17A疗法失败的患者中,使用布罗达单抗治疗中度至重度银屑病。
J Am Acad Dermatol. 2019 Sep;81(3):857-859. doi: 10.1016/j.jaad.2019.05.007. Epub 2019 May 10.
10
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.IL-17 拮抗剂的成功同类内转换:一项多中心、多国回顾性研究。
Arch Dermatol Res. 2019 Jul;311(5):421-424. doi: 10.1007/s00403-019-01907-y. Epub 2019 Mar 16.